Overcoming the cystic fibrosis sputum barrier to leading adeno-associated virus gene therapy vectors

Molecular Therapy

Volumn 22, Issue 8, 2014, Pages 1484-1493

  Schuster, Benjamin S ^a   Kim, Anthony J ^a,e   Kays, Joshua C ^a   Kanzawa, Mia M ^a   Guggino, William B ^a   Boyle, Michael P ^a   Rowe, Steven M ^b   Muzyczka, Nicholas ^c   Suk, Jung Soo ^a   Hanes, Justin ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d Johns Hopkins University   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; HEPARIN; PARVOVIRUS VECTOR;

ADULT; ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DIFFUSION; DRUG EFFECT; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HUMAN ADENOVIRUS 1; HUMAN ADENOVIRUS 2; HUMAN ADENOVIRUS 5; MALE; MICROBIAL ADHESION; SEROTYPE; SPUTUM; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS CAPSID; VIRUS ENTRY; VIRUS INFECTIVITY; VIRUS PARTICLE; VISCOELASTICITY; CELL LINE; CLASSIFICATION; DEPENDOPARVOVIRUS; DRUG EFFECTS; GENE THERAPY; GENE VECTOR; GENETICS; HEK293 CELL LINE; PHYSIOLOGY; SCANNING ELECTRON MICROSCOPY; THERAPEUTIC USE; VIROLOGY;

ADENO-ASSOCIATED VIRUS;

ACETYLCYSTEINE; CELL LINE; CYSTIC FIBROSIS; DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; HEK293 CELLS; HUMANS; MICROSCOPY, ELECTRON, SCANNING; SPUTUM;

EID: 84905442242     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.89     Document Type: Article

References (50)

1. Sosnay, PR, Siklosi, KR, Van Goor, F, Kaniecki, K, Yu, H, Sharma, N et al. (2013). Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet 45: 1160-1167.
2. O'Sullivan, BP and Freedman, SD (2009). Cystic fibrosis. Lancet 373: 1891-1904.
3. Griesenbach, U and Alton, EW (2012). Progress in gene and cell therapy for cystic fibrosis lung disease. Curr Pharm Des 18: 642-662.
4. Johnson, LG, Boyles, SE, Wilson, J and Boucher, RC (1995). Normalization of raised sodium absorption and raised calcium-mediated chloride secretion by adenovirusmediated expression of cystic fibrosis transmembrane conductance regulator in primary human cystic fibrosis airway epithelial cells. J Clin Invest 95: 1377-1382.
5. Hyde, SC, Gill, DR, Higgins, CF, Trezise, AE, MacVinish, LJ, Cuthbert, AW et al. (1993). Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy. Nature 362: 250-255.
6. Mueller, C and Flotte, TR (2008). Gene therapy for cystic fibrosis. Clin Rev Allergy Immunol 35: 164-178.
7. Sanders, N, Rudolph, C, Braeckmans, K, De Smedt, SC and Demeester, J (2009). Extracellular barriers in respiratory gene therapy. Adv Drug Deliv Rev 61: 115-127.
8. Flotte, TR, Fischer, AC, Goetzmann, J, Mueller, C, Cebotaru, L, Yan, Z et al. (2010). Dual reporter comparative indexing of rAAV pseudotyped vectors in chimpanzee airway. Mol Ther 18: 594-600.
9. Fahy, JV and Dickey, BF (2010). Airway mucus function and dysfunction. N Engl J Med 363: 2233-2247.
10. Schuster, BS, Suk, JS, Woodworth, GF and Hanes, J (2013). Nanoparticle diffusion in respiratory mucus from humans without lung disease. Biomaterials 34: 3439-3446.
11. Hida, K, Lai, SK, Suk, JS, Won, SY, Boyle, MP and Hanes, J (2011). Common gene therapy viral vectors do not efficiently penetrate sputum from cystic fibrosis patients. PLoS One 6: e19919.
12. Kitson, C, Angel, B, Judd, D, Rothery, S, Severs, NJ, Dewar, A et al. (1999). The extraand intracellular barriers to lipid and adenovirus-mediated pulmonary gene transfer in native sheep airway epithelium. Gene Ther 6: 534-546.
13. Liu, X, Yan, Z, Luo, M and Engelhardt, JF (2006). Species-specific differences in mouse and human airway epithelial biology of recombinant adeno-associated virus transduction. Am J Respir Cell Mol Biol 34: 56-64.
14. Opie, SR, Warrington, KH Jr, Agbandje-McKenna, M, Zolotukhin, S and Muzyczka, N (2003). Identification of amino acid residues in the capsid proteins of adenoassociated virus type 2 that contribute to heparan sulfate proteoglycan binding. J Virol 77: 6995-7006.
15. Walters, RW, Yi, SM, Keshavjee, S, Brown, KE, Welsh, MJ, Chiorini, JA et al. (2001). Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J Biol Chem 276: 20610-20616.
16. Wu, Z, Miller, E, Agbandje-McKenna, M and Samulski, RJ (2006). Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adenoassociated virus types 1 and 6. J Virol 80: 9093-9103.
17. Asokan, A, Schaffer, DV and Samulski, RJ (2012). The AAV vector toolkit: poised at the clinical crossroads. Mol Ther 20: 699-708.
18. Suk, JS, Lai, SK, Wang, YY, Ensign, LM, Zeitlin, PL, Boyle, MP et al. (2009). The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by nonadhesive polymer nanoparticles. Biomaterials 30: 2591-2597.
19. Kim, AJ, Boylan, NJ, Suk, JS, Hwangbo, M, Yu, T, Schuster, BS et al. (2013). Use of single-site-functionalized PEG dendrons to prepare gene vectors that penetrate human mucus barriers. Angew Chem Int Ed Engl 52: 3985-3988.
20. Berg, HC (1993). Random Walks in Biology. Princeton University Press: Princeton, NJ, pp. 152.
21. Crocker, JC and Grier, DG (1996). Methods of digital video microscopy for colloidal studies. J Colloid Interface Sci 179: 298-310.
22. Dawson, M, Wirtz, D and Hanes, J (2003). Enhanced viscoelasticity of human cystic fibrotic sputum correlates with increasing microheterogeneity in particle transport. J Biol Chem 278: 50393-50401.
23. Hamid, Q, Shannon, J and Martin, JG (2005). Physiologic Basis of Respiratory Disease. BC Decker: Hamilton, ON, pp. 793.
24. Bates, D, Maechler, M, Bolker, B and Walker, S (2014). lme4: Linear mixed-effects models using Eigen and S4. R package version 1. 1-6. http://CRAN. R-project. org/ package=lme4.
25. Suk, JS, Boylan, NJ, Trehan, K, Tang, BC, Schneider, CS, Lin, JM et al. (2011). N-acetylcysteine enhances cystic fibrosis sputum penetration and airway gene transfer by highly compacted DNA nanoparticles. Mol Ther 19: 1981-1989.
26. Suk, JS, Lai, SK, Boylan, NJ, Dawson, MR, Boyle, MP and Hanes, J (2011). Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine. Nanomedicine (Lond) 6: 365-375.
27. Solic, N, Wilson, J, Wilson, SJ and Shute, JK (2005). Endothelial activation and increased heparan sulfate expression in cystic fibrosis. Am J Respir Crit Care Med 172: 892-898.
28. Chan, SC, Shum, DK and Ip, MS (2003). Sputum sol neutrophil elastase activity in bronchiectasis: differential modulation by syndecan-1. Am J Respir Crit Care Med 168: 192-198.
29. Wu, P, Xiao, W, Conlon, T, Hughes, J, Agbandje-McKenna, M, Ferkol, T et al. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol 74: 8635-8647.
30. Kern, A, Schmidt, K, Leder, C, Müller, OJ, Wobus, CE, Bettinger, K et al. (2003). Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J Virol 77: 11072-11081.
31. Lieleg, O, Lieleg, C, Bloom, J, Buck, CB and Ribbeck, K (2012). Mucin biopolymers as broad-spectrum antiviral agents. Biomacromolecules 13: 1724-1732.
32. Auricchio, A, O'Connor, E, Hildinger, M and Wilson, JM (2001). A single-step affinity column for purification of serotype-5 based adeno-associated viral vectors. Mol Ther 4: 372-374.
33. Walters, RW, Pilewski, JM, Chiorini, JA and Zabner, J (2002). Secreted and transmembrane mucins inhibit gene transfer with AAV4 more efficiently than AAV5. J Biol Chem 277: 23709-23713.
34. Wang, YY, Kannan, A, Nunn, KL, Murphy, MA, Subramani, DB, Moench, T et al. (2014). IgG in cervicovaginal mucus traps HSV and prevents vaginal Herpes infections. Mucosal Immunol doi: 10. 1038/mi. 2013. 120 (e-pub ahead of print).
35. Chirmule, N, Propert, K, Magosin, S, Qian, Y, Qian, R and Wilson, J (1999). Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 6: 1574-1583.
36. Halbert, CL, Miller, AD, McNamara, S, Emerson, J, Gibson, RL, Ramsey, B et al. (2006). Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors. Hum Gene Ther 17: 440-447.
37. Calcedo, R, Vandenberghe, LH, Gao, G, Lin, J and Wilson, JM (2009). Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis 199: 381-390.
38. Boyle, MP, Enke, RA, Reynolds, JB, Mogayzel, PJ Jr, Guggino, WB and Zeitlin, PL (2006). Membrane-associated heparan sulfate is not required for rAAV-2 infection of human respiratory epithelia. Virol J 3: 29.
39. Mogayzel, PJ Jr, Naureckas, ET, Robinson, KA, Mueller, G, Hadjiliadis, D, Hoag, JB et al. Pulmonary Clinical Practice Guidelines Committee. (2013). Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 187: 680-689.
40. Forier, K, Messiaen, AS, Raemdonck, K, Deschout, H, Rejman, J, De Baets, F et al. (2013). Transport of nanoparticles in cystic fibrosis sputum and bacterial biofilms by single-particle tracking microscopy. Nanomedicine (Lond) 8: 935-949.
41. Button, B, Cai, LH, Ehre, C, Kesimer, M, Hill, DB, Sheehan, JK et al. (2012). A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia. Science 337: 937-941.
42. Kesimer, M, Ehre, C, Burns, KA, Davis, CW, Sheehan, JK and Pickles, RJ (2013). Molecular organization of the mucins and glycocalyx underlying mucus transport over mucosal surfaces of the airways. Mucosal Immunol 6: 379-392.
43. Virella-Lowell, I, Poirier, A, Chesnut, KA, Brantly, M and Flotte, TR (2000). Inhibition of recombinant adeno-associated virus (rAAV) transduction by bronchial secretions from cystic fibrosis patients. Gene Ther 7: 1783-1789.
44. Excoffon, KJ, Koerber, JT, Dickey, DD, Murtha, M, Keshavjee, S, Kaspar, BK et al. (2009). Directed evolution of adeno-associated virus to an infectious respiratory virus. Proc Natl Acad Sci USA 106: 3865-3870.
45. Zolotukhin, S, Potter, M, Zolotukhin, I, Sakai, Y, Loiler, S, Fraites, TJ Jr et al. (2002). Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28: 158-167.
46. Salganik, M, Aydemir, F, Nam, HJ, McKenna, R, Agbandje-McKenna, M and Muzyczka, N (2014). Adeno-associated virus capsid proteins may play a role in transcription and second-strand synthesis of recombinant genomes. J Virol 88: 1071-1079.
47. Zolotukhin, S, Byrne, BJ, Mason, E, Zolotukhin, I, Potter, M, Chesnut, K et al. (1999). Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 6: 973-985.
48. Bartlett, JS, Wilcher, R and Samulski, RJ (2000). Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J Virol 74: 2777-2785.
49. Nance, EA, Woodworth, GF, Sailor, KA, Shih, TY, Xu, Q, Swaminathan, G et al. (2012). A dense poly(ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue. Sci Transl Med 4: 149ra119.
50. Savin, T and Doyle, PS (2005). Static and dynamic errors in particle tracking microrheology. Biophys J 88: 623-638.